Clinical trials: Virus Diseases
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years
The objective of the study is to evaluate the immunogenicity and safety of SCTV01C or SCTV01E, comparing the immunogenicity data against Beta (B.1.351), Delta (B.1.617.2), Omicron (B.1.1.529) and other variants with Sinopharm…
- Trial name
- NCT05308602
- Testing
- SCTV01C, SCTV01E, mRNA vaccine manufactured by Pfizer or Moderna
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Autoimmune Diseases, Cardiovascular Disorders
Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions.
- Conditions
- Autoimmune Diseases, Cardiovascular Disorders, Diabetes Complications, Integumentary Disease
- Trial name
- NCT04684602
- Testing
- PrimePro™/ PrimeMSK™
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Thomas Advanced Medical LLC
Covid19
Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19)
Background - A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in December 2019 as the cause of a respiratory illness COVID-19 in Wuhan City, China.
- Trial name
- NCT04596839
- Testing
- Remdesivir, Standard of Care
- Where
- Bangladesh
- Volunteers
- 60 people
- Sponsor
- Dr. Md. Alimur Reza
SARS-CoV-2
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters
The main goal of Part A of this study is to assess the safety, reactogenicity, and immunogenicity of the study vaccine candidates.
- Trial name
- NCT05137236
- Testing
- mRNA-1283, mRNA-1283.211, mRNA-1273
- Where
- 17 sites in United States
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Cytomegalovirus Infections
A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
This 2 arm study will compare the efficacy of 100 days of Valcyte (900mg po daily) prophylaxis with that of no prophylaxis, under the condition of pre-emptive therapy of active CMV infection, in CMV positive renal transplant…
- Trial name
- NCT00372229
- Testing
- Valganciclovir CMV Prophylaxis, Valganciclovir (Pre-emptive CMV Therapy), Ganciclovir
- Where
- 24 sites in Austria, Germany
- Volunteers
- 299 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B
A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3389404 in Chronic Hepatitis B (CHB) Subjects
GSK3389404 is being developed for the treatment of CHB virus infection. The development goal for GSK3389404 is the establishment of a finite duration treatment that results in sustained suppression of hepatitis B virus (HBV)…
- Trial name
- NCT03020745
- Testing
- GSK3389404
- Where
- 21 sites in China, Hong Kong and 4 more
- Volunteers
- 78 people
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above
The purpose of this study is to assess the lot-to-lot consistency in terms of immunogenicity and evaluate the safety and reactogenicity of 3 lots of the RSVPreF3 OA investigational vaccine administered as a single dose in adults…
- Trial name
- NCT05059301
- Testing
- RSVPreF3 OA investigational vaccine
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults
The main aims of the study are to assess the safety, tolerability, pharmacokinetics and food effects of RV299 compared to Placebo in healthy adult participants.
- Trial name
- NCT06033612
- Testing
- RV299, Midazolam
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19, COVID-19 (SARS-CoV-2 Infection)
Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of allogeneic SARS-CoV-2-Specific T cells (LB-DTK-COV19) in patients with persistent clinical symptoms following a positive SARS-CoV-2 PCR test…
- Trial name
- NCT07709637
- Testing
- LB-DTK-COV19
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- LucasBio
Norovirus
Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children
The purpose of this study is to select the optimal formulation of the norovirus vaccine from different concentrations of virus-like particles (VLP) combined with aluminum hydroxide for further development in children.
- Trial name
- NCT02153112
- Testing
- GI.1/GII.4 (15/15), GI.1/GII.4 (15/50), GI.1/GII.4 (50/50)
- Where
- 12 sites in Colombia, Finland and 1 more
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- Takeda
HIV Infections
A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)
This study will investigate the safety and efficacy of raltegravir as a therapy for HIV-infected patients failing current therapy with 3-class antiviral resistance.
- Trial name
- NCT00293267
- Testing
- raltegravir potassium
- Volunteers
- 352 people
- Sponsor
- Merck Sharp & Dohme LLC
Smallpox
A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox
Phase 4, Observational Field Study in Patients Treated With TPOXX for Smallpox Disease
- Trial name
- NCT03972111
- Testing
- TPOXX 200Mg Capsule
- Where
- United States
- Sponsor
- SIGA Technologies
Hepatitis C
Hepatitis C Diagnosis to Treatment Management
The objective of this study is to evaluate whether sending alerts to healthcare providers and clinic staff to identify patients with untreated hepatitis C infection can increase the uptake of hepatitis C treatment.
- Trial name
- NCT05725109
- Testing
- Hepatitis C Treatment Alerts in CHORUS™, Standard of Care
- Where
- United States
- Volunteers
- 1,063 people
- Sponsor
- Epividian
Influenza, Human
A Multinational Phase III Study of CS-8958 (MARVEL)
The primary objective of this study is to confirm the efficacy of CS-8958 administered as a single inhaled low dose or single inhaled high dose by showing non-inferiority to oseltamivir phosphate using the time to alleviation of…
- Trial name
- MARVEL (NCT00803595)
- Testing
- CS-8958, oseltamivir phosphate
- Where
- 4 sites in China, Japan and 2 more
- Volunteers
- 1,002 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Haemophilus Influenzae Type B, Hepatitis B
Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)
To determine if there is an improvement in the immune response to HBsAg (hepatitis B virus) in healthy infants using a modified process in a combination Haemophilus Influenzae, type b/Hepatitis B vaccine and a currently licensed…
- Trial name
- NCT00441012
- Testing
- Comparator: Modified Process Vaccine, Comparator: COMVAX™
- Volunteers
- 546 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment
The purpose of this study is to determine the efficacy, safety and tolerability of different regimens of TMC435 with standard treatment compared to standard treatment alone in participants with chronic, genotype 1, hepatitis C…
- Trial name
- ASPIRE (NCT00980330)
- Testing
- TMC435, Peg-IFN-alfa-2a (P), Ribavirin (R)
- Where
- 78 sites in United States, Australia and 12 more
- Volunteers
- 463 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
A 14-Day Study of Racivir When Used in Combination in HIV-Infected Males
The purpose of this study is to evaluate Racivir. The safety, most effective dosage, and how the body reacts to Racivir will be studied.
- Trial name
- NCT00040300
- Testing
- Racivir
- Volunteers
- 18 people
- Sponsor
- Pharmasset
Hepatitis C Virus Infection
Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) administered for 12 or 24 weeks in adults with genotype 1 or 4…
- Trial name
- NCT02301936
- Testing
- LDV/SOF
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Gilead Sciences
Pertussis, Tetanus
Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis
Primary objective: To determine the safety and immunogenicity of tetanus and diphtheria toxoids adsorbed combined with component pertussis and inactivated poliomyelitis vaccine grown on vero cells (TdcP-IPV) compared to tetanus…
- Conditions
- Pertussis, Tetanus, Diphtheria, Poliomyelitis
- Trial name
- NCT02040636
- Testing
- Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV, Hepatitis B vaccine
- Where
- Canada
- Volunteers
- 277 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers
The purpose of this study is to evaluate the immunogenicity and safety of the investigational vaccine in the subjects during their participation in the study.
- Trial name
- NCT01987011
- Testing
- MG1109
- Where
- 4 sites in South Korea
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.